Juno Therapeutics Inc (NASDAQ:JUNO) has received an average rating of “Hold” from the twenty-one research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eighteen have issued a hold recommendation and two have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $57.93.
JUNO has been the topic of a number of recent analyst reports. BidaskClub downgraded shares of Juno Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 27th. Zacks Investment Research downgraded shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 17th. Citigroup downgraded shares of Juno Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 17th. Leerink Swann downgraded shares of Juno Therapeutics from an “outperform” rating to a “market perform” rating and raised their target price for the company from $56.00 to $87.00 in a research note on Tuesday, January 23rd. Finally, Guggenheim downgraded shares of Juno Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, January 22nd.
In other Juno Therapeutics news, EVP Robert Azelby sold 102,539 shares of the stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $86.25, for a total transaction of $8,843,988.75. Following the transaction, the executive vice president now directly owns 173,371 shares in the company, valued at $14,953,248.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 114,360 shares of company stock worth $9,857,003 over the last quarter. Company insiders own 15.08% of the company’s stock.
JUNO remained flat at $$86.96 on Wednesday. 2 shares of the company were exchanged, compared to its average volume of 5,484,542. The company has a current ratio of 3.61, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics has a 1-year low of $19.62 and a 1-year high of $87.01.
COPYRIGHT VIOLATION WARNING: “Juno Therapeutics Inc (JUNO) Receives $57.93 Average Target Price from Brokerages” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3377231/juno-therapeutics-inc-juno-receives-57-93-average-target-price-from-brokerages.html.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.